Antibodies against endogenous retroviruses promote lung cancer immunotherapy

Funding Information: We are grateful for assistance from the Advanced Light Microscopy, Advanced Sequencing, Experimental Histopathology, Biological Research, Cell Services, Proteomics, Flow Cytometry and Scientific Computing facilities at the Francis Crick Institute. The TRACERx study (ClinicaTtrials.gov: NCT01888601) is sponsored by University College London (UCL/12/0279) and has been approved by an independent research ethics committee (13/LO/1546). TRACERx is funded by Cancer Research UK (C11496/A17786) and is coordinated through the Cancer Research UK and University College London Cancer Trials Centre, which has a core grant from CRUK (C444/A15953). We gratefully acknowledge the patients and relatives who participated in the TRACERx study. We thank all site personnel, investigators, funders and industry partners who supported the generation of the data within this study. The results shown here are in whole or part based on data generated by the TCGA Research Network ( http://cancergenome.nih.gov ). The GTEx Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health and by NCI, NHGRI, NHLBI, NIDA, NIMH and NINDS. This work was supported by the Francis Crick Institute (CC2097, CC2088, CC2041 and CC2044), which receives its core funding from Cancer Research UK, the UK Medical Research Council and the Wellcome Trust. For the purpose of open access, the author has applied a CC BY public copyright licence to any author accepted manuscript version arising from this submission. This work was also supported by the Cancer Research UK Lung Cancer Centre of Excellence and the CRUK City of London Centre Award (C7893/A26233) as well as by the University College London Experimental Cancer Medicine Centre. This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 101018670). C.S. is a Royal Society Napier Research Professor (RSRP\R\210001). C.S. is funded by Cancer Research UK (TRACERx (C11496/A17786), PEACE (C416/A21999) and CRUK Cancer Immunotherapy Catalyst Network); the Cancer Research UK Lung Cancer Centre of Excellence (C11496/A30025); the Rosetrees Trust and the Butterfield and Stoneygate Trusts; the Novo Nordisk Foundation (ID16584); the Royal Society Professorship Enhancement Award (RP/EA/180007); the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre; the Cancer Research UK–University College London Centre; the Experimental Cancer Medicine Centre; the Breast Cancer Research Foundation (US); and the Mark Foundation for Cancer Research Aspire Award (grant no. 21-029-ASP). This work was supported by a Stand Up To Cancer–LUNGevity–American Lung Association Lung Cancer Interception Dream Team Translational Research Grant (grant no. SU2C-AACR-DT23-17 to S. M. Dubinett and A. E. Spira). Stand Up To Cancer is a division of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C. C.S. is in receipt of an ERC Advanced Grant (PROTEUS) from the ERC under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 835297). K.S.S.E. was supported by the European Union’s Horizon 2020 research and innovation programme under Marie Skłodowska-Curie grant agreement no. 838540 and the Royal Society (RF\ERE\210216). A.F. has received funding from the European Union’s Horizon 2020 research and innovation programme under Marie Skłodowska-Curie grant agreement no. 892360. S.d.C.T. was funded in part by a Marie Skłodowska-Curie Individual Fellowship from the European Union (MSCA-IF-2015-EF-ST 703228-iGEMMdev). T.K. is supported by the JSPS Overseas Research Fellowships Program (202060447). S.-H.L. is supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant no. HR20C0025), and a National Research Foundation of Korea (NRF) grant funded by the Korean government (Ministry of Science and ICT) (grant no. 2020R1A2C3006535). C.M.-R. is supported by the Rosetrees Trust (M630) and by the Wellcome Trust. A.M.F. is supported by Stand Up To Cancer (SU2C-AACR-DT23-17). M.A.B. is supported by Cancer Research UK and the Rosetrees Trust. K.L. is funded by the UK Medical Research Council (MR/P014712/1 and MR/V033077/1), the Rosetrees Trust and Cotswold Trust (A2437), and Cancer Research UK (C69256/A30194). N.J.B. is a fellow of the Lundbeck Foundation (R272-2017-4040) and acknowledges funding from the Aarhus University Research Foundation (AUFF-E-2018-7-14) and the Novo Nordisk Foundation (NNF21OC0071483). N. McGranahan is a Sir Henry Dale Fellow, jointly funded by the Wellcome Trust and the Royal Society (grant no. 211179/Z/18/Z), and also receives funding from Cancer Research UK, Rosetrees and the NIHR BRC at University College London Hospitals, and the Cancer Research UK–University College London Experimental Cancer Medicine Centre. M.J.-H. is a CRUK Career Establishment Awardee and has received funding from CRUK, the IASLC International Lung Cancer Foundation, the Lung Cancer Research Foundation, the Rosetrees Trust, UKI NETs, the NIHR and the NIHR UCLH Biomedical Research Centre. Funding Information: We are grateful for assistance from the Advanced Light Microscopy, Advanced Sequencing, Experimental Histopathology, Biological Research, Cell Services, Proteomics, Flow Cytometry and Scientific Computing facilities at the Francis Crick Institute. The TRACERx study (ClinicaTtrials.gov: NCT01888601) is sponsored by University College London (UCL/12/0279) and has been approved by an independent research ethics committee (13/LO/1546). TRACERx is funded by Cancer Research UK (C11496/A17786) and is coordinated through the Cancer Research UK and University College London Cancer Trials Centre, which has a core grant from CRUK (C444/A15953). We gratefully acknowledge the patients and relatives who participated in the TRACERx study. We thank all site personnel, investigators, funders and industry partners who supported the generation of the data within this study. The results shown here are in whole or part based on data generated by the TCGA Research Network (http://cancergenome.nih.gov). The GTEx Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health and by NCI, NHGRI, NHLBI, NIDA, NIMH and NINDS. This work was supported by the Francis Crick Institute (CC2097, CC2088, CC2041 and CC2044), which receives its core funding from Cancer Research UK, the UK Medical Research Council and the Wellcome Trust. For the purpose of open access, the author has applied a CC BY public copyright licence to any author accepted manuscript version arising from this submission. This work was also supported by the Cancer Research UK Lung Cancer Centre of Excellence and the CRUK City of London Centre Award (C7893/A26233) as well as by the University College London Experimental Cancer Medicine Centre. This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 101018670). C.S. is a Royal Society Napier Research Professor (RSRP\R\210001). C.S. is funded by Cancer Research UK (TRACERx (C11496/A17786), PEACE (C416/A21999) and CRUK Cancer Immunotherapy Catalyst Network); the Cancer Research UK Lung Cancer Centre of Excellence (C11496/A30025); the Rosetrees Trust and the Butterfield and Stoneygate Trusts; the Novo Nordisk Foundation (ID16584); the Royal Society Professorship Enhancement Award (RP/EA/180007); the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre; the Cancer Research UK–University College London Centre; the Experimental Cancer Medicine Centre; the Breast Cancer Research Foundation (US); and the Mark Foundation for Cancer Research Aspire Award (grant no. 21-029-ASP). This work was supported by a Stand Up To Cancer–LUNGevity–American Lung Association Lung Cancer Interception Dream Team Translational Research Grant (grant no. SU2C-AACR-DT23-17 to S. M. Dubinett and A. E. Spira). Stand Up To Cancer is a division of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C. C.S. is in receipt of an ERC Advanced Grant (PROTEUS) from the ERC under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 835297). K.S.S.E. was supported by the European Union’s Horizon 2020 research and innovation programme under Marie Skłodowska-Curie grant agreement no. 838540 and the Royal Society (RF\ERE\210216). A.F. has received funding from the European Union’s Horizon 2020 research and innovation programme under Marie Skłodowska-Curie grant agreement no. 892360. S.d.C.T. was funded in part by a Marie Skłodowska-Curie Individual Fellowship from the European Union (MSCA-IF-2015-EF-ST 703228-iGEMMdev). T.K. is supported by the JSPS Overseas Research Fellowships Program (202060447). S.-H.L. is supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant no. HR20C0025), and a National Research Foundation of Korea (NRF) grant funded by the Korean government (Ministry of Science and ICT) (grant no. 2020R1A2C3006535). C.M.-R. is supported by the Rosetrees Trust (M630) and by the Wellcome Trust. A.M.F. is supported by Stand Up To Cancer (SU2C-AACR-DT23-17). M.A.B. is supported by Cancer Research UK and the Rosetrees Trust. K.L. is funded by the UK Medical Research Council (MR/P014712/1 and MR/V033077/1), the Rosetrees Trust and Cotswold Trust (A2437), and Cancer Research UK (C69256/A30194). N.J.B. is a fellow of the Lundbeck Foundation (R272-2017-4040) and acknowledges funding from the Aarhus University Research Foundation (AUFF-E-2018-7-14) and the Novo Nordisk Foundation (NNF21OC0071483). N. McGranahan is a Sir Henry Dale Fellow, jointly funded by the Wellcome Trust and the Royal Society (grant no. 211179/Z/18/Z), and also receives funding from Cancer Research UK, Rosetrees and the NIHR BRC at University College London Hospitals, and the Cancer Research UK–University College London Experimental Cancer Medicine Centre. M.J.-H. is a CRUK Career Establishment Awardee and has received funding from CRUK, the IASLC International Lung Cancer Foundation, the Lung Cancer Research Foundation, the Rosetrees Trust, UKI NETs, the NIHR and the NIHR UCLH Biomedical Research Centre. Publisher Copyright: © 2023, The Author(s).Peer reviewedPublisher PD

An Immersive Motion Sketch Pad

GROCS: GRant Opportunities [collaborative spaces], a Digital Media Commons program to fund student research on the use of rich media in collaborative learning.http://deepblue.lib.umich.edu/bitstream/2027.42/57302/1/Cave_Capture proposal.pd

Field testing of modular borehole monitoring with simultaneous distributed acoustic sensing and geophone vertical seismic profiles at Citronelle, Alabama

A modular borehole monitoring concept has been implemented to provide a suite of well-based monitoring tools that can be deployed cost effectively in a flexible and robust package. The initial modular borehole monitoring system was deployed as part of a CO2 injection test operated by the Southeast Regional Carbon Sequestration Partnership near Citronelle, Alabama. The Citronelle modular monitoring system transmits electrical power and signals, fibre-optic light pulses, and fluids between the surface and a reservoir. Additionally, a separate multi-conductor tubing-encapsulated line was used for borehole geophones, including a specialized clamp for casing clamping with tubing deployment. The deployment of geophones and fibre-optic cables allowed comparison testing of distributed acoustic sensing. We designed a large source effort (>64 sweeps per source point) to test fibre-optic vertical seismic profile and acquired data in 2013. The native measurement in the specific distributed acoustic sensing unit used (an iDAS from Silixa Ltd) is described as a localized strain rate. Following a processing flow of adaptive noise reduction and rebalancing the signal to dimensionless strain, improvement from repeated stacking of the source was observed. Conversion of the rebalanced strain signal to equivalent velocity units, via a scaling by local apparent velocity, allows quantitative comparison of distributed acoustic sensing and geophone data in units of velocity. We see a very good match of uncorrelated time series in both amplitude and phase, demonstrating that velocity-converted distributed acoustic sensing data can be analyzed equivalent to vertical geophones. We show that distributed acoustic sensing data, when averaged over an interval comparable to typical geophone spacing, can obtain signal-to-noise ratios of 18 dB to 24 dB below clamped geophones, a result that is variable with noise spectral amplitude because the noise characteristics are not identical. With vertical seismic profile processing, we demonstrate the effectiveness of downgoing deconvolution from the large spatial sampling of distributed acoustic sensing data, along with improved upgoing reflection quality. We conclude that the extra source effort currently needed for tubing-deployed distributed acoustic sensing vertical seismic profile, as part of a modular monitoring system, is well compensated by the extra spatial sampling and lower deployment cost as compared with conventional borehole geophones

Central North Sea - CO2 Storage Hub Enabling CCS Deployment in the UK and Europe

Carbon Capture & Storage is widely recognised as a vital technology which will play a significant role in the generation of low carbon electricity. CCS has the potential to reduce the carbon emissions of fossil fuelled power stations by as much as 90% as well as offering the only realistic solution to heavy industrial emitters such as steel mills, petrochemical refineries and cement manufacturing plants. Projects which can combine capture of emissions from power generation as well industrial emitters will enable the development of CO2 transport infrastructure which can act to safeguard existing employment in carbon-intensive industries within the UK and EU. CCS development zones can also attract new energy intensive industries to locate into an area with an established network of CO2 pipelines. That means low marginal costs to connect into a guaranteed network for transportation and storage of captured CO2. Recent studies examining the levelised cost of electricity have consistently demonstrated that CCS will be competitive with renewable generation technologies such as offshore wind. CCS provides a low-carbon solution to the issue of intermittency which is inevitable with wind power, thereby helping to address the need for energy security in a future which will see a growth in the percentage of power generation from renewable sources. Fossil fuels will be part of the energy and industry system for many decades to come. CCS is the only viable option for abating those CO2 emissions. The creation of a CCS industry in the UK will provide opportunities for economic growth through the retention of many thousands of high-value jobs, creation of thousands of new jobs, increased manufacturing activity, as well as retention of the UK's world leading oil & gas supply chain for home investment and billions of pounds in export services.Carbon Capture & Storage is widely recognised as a vital technology which will play a significant role in the generation of low carbon electricity. CCS has the potential to reduce the carbon emissions of fossil fuelled power stations by as much as 90% as well as offering the only realistic solution to heavy industrial emitters such as steel mills, petrochemical refineries and cement manufacturing plants. Projects which can combine capture of emissions from power generation as well industrial emitters will enable the development of CO2 transport infrastructure which can act to safeguard existing employment in carbon-intensive industries within the UK and EU. CCS development zones can also attract new energy intensive industries to locate into an area with an established network of CO2 pipelines. That means low marginal costs to connect into a guaranteed network for transportation and storage of captured CO2. Recent studies examining the levelised cost of electricity have consistently demonstrated that CCS will be competitive with renewable generation technologies such as offshore wind. CCS provides a low-carbon solution to the issue of intermittency which is inevitable with wind power, thereby helping to address the need for energy security in a future which will see a growth in the percentage of power generation from renewable sources. Fossil fuels will be part of the energy and industry system for many decades to come. CCS is the only viable option for abating those CO2 emissions. The creation of a CCS industry in the UK will provide opportunities for economic growth through the retention of many thousands of high-value jobs, creation of thousands of new jobs, increased manufacturing activity, as well as retention of the UK's world leading oil & gas supply chain for home investment and billions of pounds in export services

Influence of Site and Operator Characteristics on Carotid Artery Stent Outcomes Analysis of the CAPTURE 2 (Carotid ACCULINK/ACCUNET Post Approval Trial to Uncover Rare Events) Clinical Study

ObjectivesThe aim of this study was to analyze the CAPTURE 2 (Carotid ACCULINK/ACCUNET Post Approval Trial to Uncover Rare Events) study for physician- or site-related variables associated with differential outcomes for carotid artery stenting (CAS).BackgroundThe CAPTURE 2 trial is an ongoing, prospective, nonrandomized, independently adjudicated, multicenter clinical study enrolling high-surgical-risk patients undergoing CAS.MethodsIn this assessment of the CAPTURE 2 study, the American Heart Association carotid endarterectomy guideline limits were used to define acceptable site and physician CAS outcomes; therefore, the resulting population of nonoctogenarian, asymptomatic subjects in this analysis is confined to 3,388 (of the total 5,297) subjects treated at 180 U.S. hospitals by 459 operators between March 2006 and January 2009.ResultsThe rates of death, stroke, and myocardial infarction and death and stroke (DS) at 30 days were 3.5% and 3.3%, respectively, for the full CAPTURE 2 study cohort and 2.9% and 2.7%, respectively, for the asymptomatic, nonoctogenarian subgroup. In this subgroup, two-thirds of sites (118 of 180, 66%) had no DS events. Within the remaining sites, an inverse relationship between event rates and hospital patient volume as well as between event rates and individual operator volume was observed. The DS rates trended lower for interventional cardiologists compared with other specialties.ConclusionsOutcomes from the largest prospectively gathered, independently adjudicated, multicenter CAS study indicate that CAS can be safely performed in a variety of hospital settings by physicians with various specialties. The most important determinant of perioperative CAS outcomes was both site and operator CAS volume. A threshold of 72 cases was found to be necessary for consistently achieving a DS rate below 3% in this later-phase single arm study; background era and non-study operator experience will affect this determination.(Second Phase of “Carotid RX ACCULINK/RX ACCUNET Post-Approval Trial to Uncover Unanticipated or Rare Events”; NCT00302237

Exploiting depth information for fast motion and disparity estimation in multi-view video coding

This research work is partially funded by the Strategic Educational Pathways Scholarship Scheme (STEPS-Malta). This scholarship is partly financed by the European Union – European Social Fund (ESF 1.25).Multi-view Video Coding (MVC) employs both motion and disparity estimation within the encoding process. These provide a significant increase in coding efficiency at the expense of a substantial increase in computational requirements. This paper presents a fast motion and disparity estimation technique that utilizes the multi-view geometry together with the depth information and the corresponding encoded motion vectors from the reference view, to produce more reliable motion and disparity vector predictors for the current view. This allows for a smaller search area which reduces the computational cost of the multi-view encoding system. Experimental results confirm that the proposed techniques can provide a speed-up gain of up to 4.2 times, with a negligible loss in the rate-distortion performance for both the color and the depth MVC.peer-reviewe